Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Martinez, Erin E ^a   Anderson, Philip D ^a   Logan, Monica ^b   Abdulkadir, Sarki A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; PROTEIN NKX3.1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DYSPLASIA; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MOUSE MUTANT; NONHUMAN; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; TUMOR GROWTH;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; CELL PROLIFERATION; GENE DELETION; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; MALE; MICE; OXIDATIVE STRESS; PROSTATE; PROSTATIC HYPERPLASIA; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS;

EID: 84867542182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046792     Document Type: Article

References (74)

1. Fleshner NE, Klotz LH, (1998) Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 17: 325-330.
2. Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TRL, et al. (2005) Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer 41: 61-70 doi:10.1016/j.ejca.2004.09.028.
3. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK, (2009) Oxidative stress in prostate cancer. Cancer Lett 282: 125-136 doi:10.1016/j.canlet.2008.12.011.
4. Ozten-Kandaş N, Bosland MC, (2011) Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants- In vivo evidence. J Carcinog 10: 27 doi:10.4103/1477-3163.90438.
5. Sfanos KS, De Marzo AM, (2012) Prostate cancer and inflammation: the evidence. Histopathology 60: 199-215 doi:10.1111/j.1365-2559.2011.04033.x.
6. Thapa D, Ghosh R, (2012) Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 83: 1319-1330 doi:10.1016/j.bcp.2011.12.027.
7. Nyska A, Suttie A, Bakshi S, Lomnitski L, Grossman S, et al. (2003) Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural anti-oxidant from spinach, NAO-a comparative study of three anti-oxidants. Toxicol Pathol 31: 39-51.
8. Tam NNC, Nyska A, Maronpot RR, Kissling G, Lomnitski L, et al. (2006) Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate 66: 57-69 doi:10.1002/pros.20313.
9. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, et al. (2012) Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 187: 707-714 doi:10.1016/j.juro.2011.09.147.
10. Adhami VM, Ahmad N, Mukhtar H, (2003) Molecular targets for green tea in prostate cancer prevention. J Nutr 133: 2417S-2424S.
11. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH, (2004) Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 64: 5891-5896 doi:10.1158/0008-5472.CAN-04-0690.
12. Barve A, Khor TO, Nair S, Reuhl K, Suh N, et al. (2009) Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 124: 1693-1699 doi:10.1002/ijc.24106.
13. Narayanan NK, Nargi D, Randolph C, Narayanan BA, (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125: 1-8 doi:10.1002/ijc.24336.
14. Khan N, Adhami VM, Afaq F, Mukhtar H (2012) Butein Induces Apoptosis and Inhibits Prostate Tumor Growth In Vitro and In Vivo. Antioxidants & Redox Signaling. Available:http://www.ncbi.nlm.nih.gov/pubmed/22114764. Accessed 2012 Mar 15.
15. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, et al. (2001) SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166: 1311-1315.
16. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, et al. (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91: 608-612.
17. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, et al. (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440-446.
18. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51 doi:10.1001/jama.2008.864.
19. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556 doi:10.1001/jama.2011.1437.
20. Klein EA, (2009) Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst 101: 283-285 doi:10.1093/jnci/djp009.
21. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, et al. (2000) Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60: 6111-6115.
22. Asatiani E, Huang W-X, Wang A, Rodriguez Ortner E, Cavalli LR, et al. (2005) Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 65: 1164-1173 doi:10.1158/0008-5472.CAN-04-2688.
23. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, et al. (1997) A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43: 69-77 doi:10.1006/geno.1997.4715.
24. Chen H, Nandi AK, Li X, Bieberich CJ, (2002) NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62: 338-340.
25. Abdulkadir SA, (2005) Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1. Ann N Y Acad Sci 1059: 33-40 doi:10.1196/annals.1339.018.
26. Magee JA, Abdulkadir SA, Milbrandt J, (2003) Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 3: 273-283.
27. Tan PY, Chang CW, Chng KR, Wansa KDSA, Sung W-K, et al. (2012) Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol 32: 399-414 doi:10.1128/MCB.05958-11.
28. Bowen C, Gelmann EP, (2010) NKX3.1 activates cellular response to DNA damage. Cancer Res 70: 3089-3097 doi:10.1158/0008-5472.CAN-09-3138.
29. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500 doi:10.1038/nature08361.
30. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, et al. (2009) Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28: 3307-3319 doi:10.1038/onc.2009.181.
31. Muhlbradt E, Asatiani E, Ortner E, Wang A, Gelmann EP, (2009) NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Res 69: 2615-2622 doi:10.1158/0008-5472.CAN-08-3022.
32. Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, et al. (2008) Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res 68: 8770-8778 doi:10.1158/0008-5472.CAN-08-1912.
33. Bowen C, Stuart A, Ju J-H, Tuan J, Blonder J, et al. (2007) NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 67: 455-464 doi:10.1158/0008-5472.CAN-06-1591.
34. Lei Q, Jiao J, Xin L, Chang C-J, Wang S, et al. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367-378 doi:10.1016/j.ccr.2006.03.031.
35. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, et al. (1999) Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13: 966-977.
36. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, et al. (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22: 1495-1503.
37. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, et al. (2002) Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62: 2999-3004.
38. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, et al. (2002) Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99: 2884-2889 doi:10.1073/pnas.042688999.
39. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C, (2005) Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65: 6773-6779 doi:10.1158/0008-5472.CAN-05-1948.
40. Bethel CR, Faith D, Li X, Guan B, Hicks JL, et al. (2006) Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res 66: 10683-10690 doi:10.1158/0008-5472.CAN-06-0963.
41. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, et al. (2010) Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 176: 2259-2268 doi:10.2353/ajpath.2010.080747.
42. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315 doi:10.1093/bioinformatics/btg405.
43. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264 doi:10.1093/biostatistics/4.2.249.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550 doi:10.1073/pnas.0506580102.
45. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T, (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432 doi:10.1093/bioinformatics/btq675.
46. Merico D, Isserlin R, Stueker O, Emili A, Bader GD, (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5: e13984 doi:10.1371/journal.pone.0013984.
47. Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, et al. (2012) Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 122: 1907-1919 doi:10.1172/JCI58540.
48. Kondo S, Toyokuni S, Iwasa Y, Tanaka T, Onodera H, et al. (1999) Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med 27: 401-410.
49. Pan J-S, Hong M-Z, Ren J-L, (2009) Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroenterol 15: 1702-1707.
50. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273 doi:10.1038/ng1180.
51. Graham SM, Vass JK, Holyoake TL, Graham GJ, (2007) Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25: 3111-3120 doi:10.1634/stemcells.2007-0250.
52. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, et al. (2005) Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24: 7094-7104 doi:10.1038/sj.onc.1208854.
53. Vindrieux D, Escobar P, Lazennec G, (2009) Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16: 663-673 doi:10.1677/ERC-09-0109.
54. Singh RK, Sudhakar A, Lokeshwar BL, (2010) Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression. J Cancer Sci Ther 2: 89-94 doi:10.4172/1948-5956.1000030.
55. Nelson J, Bagnato A, Battistini B, Nisen P, (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116 doi:10.1038/nrc990.
56. Ruscica M, Dozio E, Motta M, Magni P, (2007) Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 28: 426-434 doi:10.1016/j.peptides.2006.08.045.
57. De Flora S, Izzotti A, D'Agostini F, Balansky RM, (2001) Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22: 999-1013.
58. Aitio M-L, (2006) N-acetylcysteine-passe-partout or much ado about nothing? Br J Clin Pharmacol 61: 5-15 doi:10.1111/j.1365-2125.2005.02523.x.
59. Kim TH, Oh S, Kim SS, (2005) Recombinant human prothrombin kringle-2 induces bovine capillary endothelial cell cycle arrest at G0-G1 phase through inhibition of cyclin D1/CDK4 complex: modulation of reactive oxygen species generation and up-regulation of cyclin-dependent kinase inhibitors. Angiogenesis 8: 307-314 doi:10.1007/s10456-005-9020-y.
60. Chen C-Y, Chen C-H, Lo Y-C, Wu B-N, Wang H-M, et al. (2008) Anticancer activity of isoobtusilactone A from Cinnamomum kotoense: involvement of apoptosis, cell-cycle dysregulation, mitochondria regulation, and reactive oxygen species. J Nat Prod 71: 933-940 doi:10.1021/np070620e.
61. Li M, Zhao L, Liu J, Liu A-L, Zeng W-S, et al. (2009) Hydrogen peroxide induces G2 cell cycle arrest and inhibits cell proliferation in osteoblasts. Anat Rec (Hoboken) 292: 1107-1113 doi:10.1002/ar.20925.
62. Chaudhuri L, Sarsour EH, Kalen AL, Aykin-Burns N, Spitz DR, et al. (2010) Polychlorinated biphenyl induced ROS signaling delays the entry of quiescent human breast epithelial cells into the proliferative cycle. Free Radic Biol Med 49: 40-49 doi:10.1016/j.freeradbiomed.2010.03.012.
63. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, et al. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109 doi:10.1038/nature10189.
64. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, et al. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765 doi:10.1038/nature07823.
65. McCormick DL, Rao KVN, Johnson WD, Bosland MC, Lubet RA, et al. (2010) Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila) 3: 381-392 doi:10.1158/1940-6207.CAPR-09-0176.
66. Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, et al. (2010) A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 19: 4265-4272 doi:10.1093/hmg/ddq350.
67. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, et al. (2008) Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29: 2335-2340 doi:10.1093/carcin/bgn212.
68. Quick SK, Shields PG, Nie J, Platek ME, McCann SE, et al. (2008) Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 1082-1087 doi:10.1158/1055-9965.EPI-07-2755.
69. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, et al. (2011) Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 107: 126-134 doi:10.1111/j.1464-410X.2010.09344.x.
70. Zhang J, Dhakal IB, Greene G, Lang NP, Kadlubar FF, (2010) Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 75: 779-785 doi:10.1016/j.urology.2009.08.063.
71. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, et al. (2005) Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65: 2498-2504 doi:10.1158/0008-5472.CAN-04-3535.
72. McNeil C, (2011) Vitamin E and prostate cancer: research focus turns to biologic mechanisms. J Natl Cancer Inst 103: 1731-1734 doi:10.1093/jnci/djr504.
73. Kim J, Eltoum I-EA, Roh M, Wang J, Abdulkadir SA, (2009) Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 5: e1000542 doi:10.1371/journal.pgen.1000542.
74. Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum I-EA, et al. (2012) A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 31: 322-332 doi:10.1038/onc.2011.236.